AngelesAlvarezSecordMD

Obstetrics & Gynecology • Durham, NC

Gynecologic Oncology

Professor, Obstetrics & Gynecology, Duke University School of Medicine

Join to view full profile

Dr. Secord is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Secord's full profile

Already have an account?

Office
20 Duke Medicine Circle
Durham, NC 27710
Phone+1 919-684-3765
Is this information wrong?

Education & Training

Duke University HospitalFellowship, Gynecologic Oncology, 1998 - 2001
Duke University HospitalResidency, Obstetrics and Gynecology, 1994 - 1998
University of Washington School of MedicineClass of 1994

Certifications & Licensure

NC State Medical License 1998 - 2025
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Fellow (FACOG) American Congress of Obstetricians and Gynecologists

Clinical Trials

Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer Start of enrollment: 2004 Jun 01
Completed
Phase 2
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer Start of enrollment: 2003 Oct 01
Completed
Phase 2
A Phase I Study of Ovarian Cancer Peptides Plus GM-CSF and Adjuvant With Ovarian, Tubal or Peritoneal Cancer Start of enrollment: 2007 Mar 01
Completed
Phase 1
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2007 Dec 06
Active, not recruiting
Phase 3
PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer Start of enrollment: 2007 Aug 01
Completed
Phase 1
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Start of enrollment: 2009 Mar 23
Active, not recruiting
Phase 3
Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2010 Dec 13
Completed
Phase 2
Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors Start of enrollment: 2010 Feb 08
Active, not recruiting
Phase 2
Ovarian Cancer Vaccine for Patients in Remission Start of enrollment: 2010 Jul 01
Completed
Phase 2
Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy Start of enrollment: 2010 Apr 01
Completed
Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Start of enrollment: 2012 Jun 04
Terminated
Phase 3
BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer Start of enrollment: 2013 Feb 01
Completed
Phase 2
Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Start of enrollment: 2014 Mar 17
Active, not recruiting
Phase 2, Phase 3
Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Start of enrollment: 2014 Feb 27
Active, not recruiting
Phase 2, Phase 3
Endometrial Cancer Diet and Exercise Start of enrollment: 2017 Feb 01
Completed
Not Applicable
Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer Start of enrollment: 2018 Jun 19
Completed
Phase 1, Phase 2
A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208) Start of enrollment: 2019 Mar 20
Completed
Phase 2
Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer Start of enrollment: 2021 Nov 29
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

1336 citations
Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.
Katherine A Hoadley, Christina Yau, Toshinori Hinoue, Denise M. Wolf, Alexander J. Lazar
Cell. 2018-04-05
308 citations
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
Kathleen N. Moore, Angeles Alvarez Secord, Melissa A. Geller, David Miller, N.G. Cloven
The Lancet. Oncology. 2019-05-01
46 citations
A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peri...
Bradley J. Monk, James Kauderer, Katherine M. Moxley, Albert J. Bonebrake, Summer B. Dewdney
Gynecologic Oncology. 2018-12-01

Journal Articles

Differential Expression of Immune Related Genes in High-Grade Ovarian Serous Carcinoma
Rebecca A Previs, Angeles Alvarez Secord, Gynecologic Oncology

Other

Classification and treatment of endometrial stromal tumors
Secord AA, Gaillard S
http://www.uptodate.com/contents/classification-and-treatment-of-endometrial-stromal-tumors
UpToDate, Wolters Kluwer Health - 2013-04-10

Press Mentions

What Can We Do About Health Disparities in the Diagnosis and Treatment of Endometrial Cancer?August 27th, 2024
Quest PharmaTech Announces Two Presentations by OncoQuest Pharmaceuticals, Inc. At the 2021 Annual Meeting of the American Association of Clinical OncologistsJune 1st, 2021
Secord Shares Data to Digest with PARP Inhibitors in Ovarian CancerFebruary 9th, 2020
Join now to see all